Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool August 16, 2007 Lawrence Rothman	Longs' Prescription for Success Longs Drug Stores may be small, but it excels in its regional niche. Operating primarily on the West Coast, second-quarter results show a company with lots of room for growth.
The Motley Fool September 22, 2006 Ryan Fuhrmann	More in Store at Rite Aid? The retail pharmacy posted strong second-quarter sales, and an acquisition could help long-term results. Investors, take note.
The Motley Fool June 28, 2005 Mike Cianciolo	Just What Investors Prescribed With another quarter of stellar growth at Walgreen, the stock approaches its highest price ever.
The Motley Fool January 3, 2006 Stephen D. Simpson	Walgreen Reaps Rewards of Rx The nation's top pharmacy keeps on rolling, but investors might want to keep an eye on the new ventures.
The Motley Fool August 31, 2011 Shubh Datta	CVS Caremark Flattened by Higher Costs CVS Caremark profits remained relatively flat this quarter despite a substantial increase in revenue.
The Motley Fool January 5, 2007 Matthew Crews	Rite Aid's Baby Steps If Rite Aid does manage 5% operating margins, this pharmacy chain's shares will get the love they deserve.
The Motley Fool December 11, 2006 Matthew Crews	Rite Aid: Comps Mean Competition The pharmacy chain reported positive same-store results for November. Investors, take note.
The Motley Fool June 29, 2007 Ryan Fuhrmann	Rite Aid's Recent Remedy Will increased market clout lead the drugstore operator to new highs? Investors, take note.
The Motley Fool January 3, 2005 Nathan Slaughter	Walgreen Seeing Green Rivals CVS and Rite Aid have a bitter pill to swallow as Walgreen stays strong. While Walgreen's revenues were in line with forecasts, the stronger-than-expected bottom line has the stock gaining ground.
The Motley Fool September 14, 2006 Ryan Fuhrmann	Playing Defense With the Drugstore Industry Retail pharmacy August sales trends help investors discern the leader in this appealing sector.
The Motley Fool September 26, 2006 Ryan Fuhrmann	Jaw-Dropping Pill-Popping at Walgreen How much longer can investors count on Walgreen's stellar numbers?
The Motley Fool March 28, 2005 Alyce Lomax	A Cool Quarter for Walgreen Are second-quarter earnings putting a damper on Walgreen?
The Motley Fool November 9, 2005 Steven Mallas	CVS Needs Rx for Cash The drugstore chain has the prescription for earnings growth, but investors need to keep an eye on free cash flow.
The Motley Fool December 21, 2007 Timothy M. Otte	Walgreen Shapes Up for 2008 The drugstore chain reports lower expenses in the first quarter while pumping up sales.
The Motley Fool May 18, 2007 Timothy M. Otte	Longs Drug Scores a Winner The West Coast retail drug chain expands its gross margin and beats analyst estimates.
The Motley Fool June 26, 2007 Ryan Fuhrmann	Walgreen Sells Convenience Walgreen continues to grow market share, with little sign of slowing down.
The Motley Fool March 23, 2011 Andrew Bond	What More Can You Ask of Walgreen? A sell-off in shares of Walgreen provides a buying opportunity for investors who want in on a best-of-breed company at a discount.
The Motley Fool September 27, 2005 Nathan Slaughter	All Green for Walgreen The retail pharmacy posts record earnings and sales for the 31st consecutive year. Even though Walgreen's latest numbers came up a little short of the mark, it wasn't enough to capture the attention of value investors.
The Motley Fool September 29, 2010 Andrew Bond	Walgreen Surprises the Experts Walgreen posts a great quarter as competition falters.
The Motley Fool October 31, 2008 Timothy M. Otte	CVS Caremark Takes Care of Its Investors The drugstore giant continues to scoop up market share.
The Motley Fool July 6, 2004 Alyce Lomax	Not Ready for Rite Aid Can the drugstore chain hold a candle to the competition? Its shares are trading at 22 times forward earnings, making it a seemingly less-than-advantageous time to place a bet on them.
The Motley Fool January 5, 2004 Jeff Hwang	Prescriptions Boost Walgreen Earnings and sales bumped by early flu season and improved non-pharmacy sales.
The Motley Fool July 6, 2007 Timothy M. Otte	Drugstore Sales Remain Healthy The big four drugstore chains report higher comparable sales in June. Walgreen... CVS... Rite Aid... Long's...
The Motley Fool March 22, 2004 Alyce Lomax	Walgreen's Green Quarter Investors take an earnings miss to heart. But the future looks good.
The Motley Fool December 26, 2006 Matthew Crews	Walgreen Represents This drugstore business has proven itself; does its stock match up?
The Motley Fool March 5, 2004 Dave Marino-Nachison	Longs Coming Up Short Investors who bid on a Longs buyout haven't been rewarded in recent months.
The Motley Fool July 14, 2008 Rick Aristotle Munarriz	4 Stocks That Took a Hike These stocks recently raised their dividends: CVS Caremark... Paychex... Walgreen... Cummins...
The Motley Fool March 26, 2010 Cathy Applefeld Olson	Can CVS Caremark Win the Drug Wars? Now that health-care legislation has been signed into law, it's a perfect time to give the country's largest drugstore chain a checkup.
The Motley Fool March 6, 2008 Timothy M. Otte	Longs Drugs Has a Nice Niche West Coast regional drugstore chain scores solid fourth quarter.
The Motley Fool February 2, 2005 Alyce Lomax	CVS's Shot in the Arm Buying the Eckerd drugstore chain from J.C. Penney was apparently a good move for CVS. It continues to benefit from the purchase, reporting positive earnings and beating analysts' expectations by a penny.
The Motley Fool October 2, 2007 Lawrence A. Rothman	Can the Right Prescription Heal Walgreen? Walgreen is suffering from heightened competition, expenses rising more than 11%, and the company itself predicting its challenges will probably continue into the near future.
The Motley Fool June 18, 2007 Rich Duprey	Foolish Forecast: Walgreens Prescribes Growth The drugstore and convenience shop chain will report its third-quarter 2007 financial results shortly. Investors, here is what you can expect to see.
The Motley Fool March 24, 2004 Dave Marino-Nachison	Eking Out an Eckerd Deal Investors are still waiting for a new leader to be crowned in the U.S. drugstore business.
The Motley Fool April 13, 2007 Ryan Fuhrmann	Rite Aid's Right-Size Ambitions If the retail pharmacy chain can improve its net margins, reduce debt, and smoothly integrate its latest acquisition, the stock's upside would be substantial.
The Motley Fool March 26, 2007 Ryan Fuhrmann	Addicted to Growth at Walgreen Walgreen is a steady grower, but that comes at a price. Investors, take note.
The Motley Fool July 5, 2005 Alyce Lomax	Business As Usual at Walgreen Walgreen's same-store sales for June certainly don't disappoint. Investors might question whether the retail pharmacy can keep up the great work.
The Motley Fool June 14, 2010 Rich Smith	Is CVS' $2 Billion Buyback Good Medicine? Don't assume just because CVS is buying its stock, that this is a good idea.
The Motley Fool January 7, 2010 Gerard Torres	Walgreen Lives to Fight Another Day Despite recent success, Walgreen continues to face stiff competition.
The Motley Fool June 2, 2004 Alyce Lomax	Walgreen's Mellow May Will the drugstore chain get a taste of its own medicine?
The Motley Fool March 22, 2010 Dave Mock	A Big Upgrade for CVS Caremark This bullish call comes from more than just one analyst.
The Motley Fool March 9, 2004 Alyce Lomax	February Frenzy at CVS, Rite Aid The flu season's early end hasn't stopped drugstore retailers.
The Motley Fool April 9, 2007 Mike Cianciolo	CVS: Continued Vigorous Sales The drugstore chain grows sales and itself in March. Investors, take note.
The Motley Fool March 24, 2011 Rick Aristotle Munarriz	It's a Dot-Com Drug Deal Gone Bad The drugstore giant acquires the drugstore.com pipsqueak.
The Motley Fool September 21, 2006 Vitaliy Katsenelson	Don't Hit the Panic Button Just Yet Wall Street plays the overreacting game; Walgreen and CVS suffer. These stocks have big tailwinds behind them.
The Motley Fool November 2, 2006 Ryan Fuhrmann	CVS Blazes a New Healthcare Trail Strong third-quarter earnings aside, the merger announcement with pharmacy benefit manager Caremark was the real shocker here. Investors, take note.
The Motley Fool April 4, 2007 Timothy M. Otte	Walgreen's Comp Machine The drugstore operator steams through March with 8% comparable sales growth. The stock trades at a P/E of 24 times trailing-12-month earnings, about one-third higher than the average of all S&P 500 companies.
The Motley Fool June 21, 2004 Seth Jayson	Walgreen's Fine Follow-Up It's another solid quarter for America's soon-to-be No. 2 drugstore.
The Motley Fool April 6, 2006 Stephen D. Simpson	Rite Aid Regains Respectability The pharmacy's slow, steady turnaround may not be enough. There have been so many dilutive financing events that it's no longer clear whether common equity shareholders will gain enough bang to compensate for the risk.
The Motley Fool August 15, 2005 Bobby Shethia	Walgreen's Prescription for Success The drugstore chain's smart and steady growth makes it a good choice for investors.
The Motley Fool November 5, 2007 Timothy M. Otte	CVS Is in the Zone Pharmacy giant CVS grew EPS by 36% in the third quarter. The company has been on a roll since its merger with Caremark last year.